Research programme: diabetes/obesity therapy - Bayer/CuraGen
Alternative Names: BAY 76-7171; CT052Latest Information Update: 17 Apr 2009
Price :
$50 *
At a glance
- Originator Bayer; CuraGen Corporation
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 17 Apr 2009 No development reported - Preclinical for Diabetes mellitus in USA (PO)
- 23 Dec 2005 The collaboration agreement between Bayer and CuraGen has been revised
- 28 Oct 2004 Bayer and CuraGen announced that an orally active, small molecule compound has been advanced into preclinical development for type 2 diabetes